| Recruiting | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent NCT06447103 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Terminated | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer NCT03260504 | University of Washington | Phase 1 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Terminated | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer NCT02767921 | University of Southern California | Phase 1 |
| Unknown | Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs NCT03630692 | Institut Cancerologie de l'Ouest | — |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer NCT02664883 | University of Southern California | — |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Unknown | Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors NCT02526511 | Rutgers, The State University of New Jersey | N/A |
| Completed | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, NCT02318771 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752 | Emory University | Phase 2 |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Withdrawn | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer NCT01769885 | Roswell Park Cancer Institute | N/A |
| Completed | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Can NCT01727076 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Ki NCT01688973 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by NCT01548482 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies NCT01243359 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanc NCT01198184 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer NCT01158521 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does N NCT01582009 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastat NCT01061411 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced NCT01026337 | Abramson Cancer Center at Penn Medicine | — |
| Terminated | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer NCT00684996 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tu NCT00499135 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors NCT00335556 | Children's Oncology Group | Phase 2 |
| Completed | Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00354250 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer NCT00324740 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer NCT00324870 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer NCT00182702 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT00098618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00101114 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer NCT00060307 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer NCT00032188 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |